ArticleBMC cancer2017

The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.

D J Lundon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.